Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytok...

Descripción completa

Detalles Bibliográficos
Autores principales: Seber, Adriana, de CastroJunior, Claudio Galvão, Kerbauy, Lucila N., Hirayama, Alexandre V., Bonfim, Carmem, Fernandes, Juliana Folloni, Souza, Mair, Schafell, Rony, Nabhan, Samir, Loggetto, Sandra Regina, Simões, Belinda Pinto, Rocha, Vanderson, de Lima, Marcos, Guerino-Cunha, Renato L., Bittencourt, Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606700/
https://www.ncbi.nlm.nih.gov/pubmed/34794791
http://dx.doi.org/10.1016/j.htct.2021.09.002
_version_ 1784602389900165120
author Seber, Adriana
de CastroJunior, Claudio Galvão
Kerbauy, Lucila N.
Hirayama, Alexandre V.
Bonfim, Carmem
Fernandes, Juliana Folloni
Souza, Mair
Schafell, Rony
Nabhan, Samir
Loggetto, Sandra Regina
Simões, Belinda Pinto
Rocha, Vanderson
de Lima, Marcos
Guerino-Cunha, Renato L.
Bittencourt, Henrique
author_facet Seber, Adriana
de CastroJunior, Claudio Galvão
Kerbauy, Lucila N.
Hirayama, Alexandre V.
Bonfim, Carmem
Fernandes, Juliana Folloni
Souza, Mair
Schafell, Rony
Nabhan, Samir
Loggetto, Sandra Regina
Simões, Belinda Pinto
Rocha, Vanderson
de Lima, Marcos
Guerino-Cunha, Renato L.
Bittencourt, Henrique
author_sort Seber, Adriana
collection PubMed
description Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.
format Online
Article
Text
id pubmed-8606700
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-86067002021-11-29 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia Seber, Adriana de CastroJunior, Claudio Galvão Kerbauy, Lucila N. Hirayama, Alexandre V. Bonfim, Carmem Fernandes, Juliana Folloni Souza, Mair Schafell, Rony Nabhan, Samir Loggetto, Sandra Regina Simões, Belinda Pinto Rocha, Vanderson de Lima, Marcos Guerino-Cunha, Renato L. Bittencourt, Henrique Hematol Transfus Cell Ther Special Article Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL. Sociedade Brasileira de Hematologia e Hemoterapia 2021-11 2021-11-16 /pmc/articles/PMC8606700/ /pubmed/34794791 http://dx.doi.org/10.1016/j.htct.2021.09.002 Text en © 2021 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Special Article
Seber, Adriana
de CastroJunior, Claudio Galvão
Kerbauy, Lucila N.
Hirayama, Alexandre V.
Bonfim, Carmem
Fernandes, Juliana Folloni
Souza, Mair
Schafell, Rony
Nabhan, Samir
Loggetto, Sandra Regina
Simões, Belinda Pinto
Rocha, Vanderson
de Lima, Marcos
Guerino-Cunha, Renato L.
Bittencourt, Henrique
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title_full Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title_fullStr Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title_full_unstemmed Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title_short Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
title_sort associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. ii: car-t cell therapy for patients with cd19+ acute lymphoblastic leukemia
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606700/
https://www.ncbi.nlm.nih.gov/pubmed/34794791
http://dx.doi.org/10.1016/j.htct.2021.09.002
work_keys_str_mv AT seberadriana associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT decastrojuniorclaudiogalvao associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT kerbauylucilan associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT hirayamaalexandrev associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT bonfimcarmem associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT fernandesjulianafolloni associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT souzamair associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT schafellrony associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT nabhansamir associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT loggettosandraregina associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT simoesbelindapinto associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT rochavanderson associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT delimamarcos associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT guerinocunharenatol associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia
AT bittencourthenrique associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia

Ejemplares similares